Impact500 empowers sustainable prescribing throughout the NHS and enables the effective implementation of medications validated to improve patient outcomes and reduce the NHS carbon footprint.

Impact500 will empower manufacturers and the NHS by:

Identification:
Which medications have a positive clinical impact for each pathway.

Monitoring:
Ensuring patients are effectively monitored.

Patient engagement:
This programme empowers patients to become actively involved in their own medicines optimisations.

Analysis:
Assessing the uptake and impact of each pathway by each GP surgery / PCN / ICS.

Carbon Optimisation:
Through effective prescribing, admissions reduction and active tree planting

Training:
NMOS (National Medicines Optimisation Service) training academy being launched in November.

500:
£500 million in savings for the NHS and reduction in carbon emissions by 500 thousand tonnes a year.

Key features of impact500 include:

• The ability to integrate with all Principal Clinical Systems (EMIS, SystmOne, Vision and Microtest).

• Full synchronisation with the DM&D and ePACT to enable and validate the delivery of over £500 million of savings for the NHS.

• The programme is available free of charge to all GP Practices, PCNs, CCGs, CSUs and ICSs. in England with plans to expand to Scotland, Wales and Northern Ireland.

• NHS cost-effective brand utilisation / carbon reduction is dramatically enhanced.

Manufacturers

Supporting and associated with a national
cost-effective prescribing programme.

NHS REGIONS

Enhanced implementation capabilities and patient specific validation within a non-identifiable environment.

GP PRACTICES

Enhanced project implementation capability, patient level sign-off and validation.

PATIENTS

Benefit from fully informed prescribing decisions and improved NHS resource utilisation.

nhs

A minimum of £500 million in savings, rapid implementation and validated outcomes.

BACKGROUND

The NHS produces over 5% of the UK’s greenhouse gases and spends over £50 million each year on Carbon Permits. Procurement of pharmaceuticals contributes 22% of the entire carbon footprint of the NHS.* Our mission is to empower the NHS long term carbon targets by working in collaboration with NHS Suppliers, Providers and Patients to ensure that our NHS can continue to deliver clinical excellence with a Carbon friendly footprint.

High quality cost-effective brands are often overlooked by the NHS resulting in growing prescribing costs and significant optimisation opportunities being missed.

The reasons are:

1. Lack of a centralised cost-effective brand optimisation programme and focus.

2. Inability for NHS organisations to rapidly identify those patients in need of optimisation.

3. Lack of education and awareness for prescribers regarding the benefits of cost-effective branded prescribing.

4. Inability to communicate effectively with end prescribers.

5. Inability to enable rapid implementation of all suitable patients.

6. Inability to validate the savings generated from cost-effective prescribing.

7. Inability to keep up with monthly pricing variations.